{
    "clinical_study": {
        "@rank": "14913", 
        "arm_group": {
            "arm_group_label": "Pregnant Women"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect maternal blood samples from pregnant women carrying\n      a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including\n      microdeletions in order to further develop a non-invasive prenatal screening test based on\n      fetal DNA isolated from maternal blood."
        }, 
        "brief_title": "Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Trisomy 21", 
            "Trisomy 18", 
            "Trisomy 13", 
            "Sex Chromosome Abnormalities", 
            "Microdeletion Syndromes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Chromosome Aberrations", 
                "Chromosome Disorders", 
                "Down Syndrome", 
                "Sex Chromosome Aberrations", 
                "Trisomy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 or older at enrollment\n\n          -  Singleton pregnancy\n\n          -  Fetus with confirmed diagnosis of chromosomal abnormality or genetic disorder through\n             karyotype, FISH or positive microarray results after amniocentesis or chorionic\n             villus testing\n\n          -  The biological father of the fetus at least 18 years of age\n\n          -  Able to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Women carrying multiples\n\n          -  Pregnancy is a result of IVF with pre-implantation genetic diagnosis\n\n          -  Surrogate/egg or sperm donor used\n\n          -  Previous participation in this study during a previous pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852708", 
            "org_study_id": "12-014-NPT"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Carlos", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94070"
                }, 
                "name": "Natera, Inc."
            }, 
            "investigator": {
                "last_name": "Zachary Demko, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood", 
        "overall_contact": {
            "email": "research@natera.com", 
            "last_name": "Melissa Savage", 
            "phone": "650-249-9090", 
            "phone_ext": "x411"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852708"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Natera, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Natera, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}